COPD drugsgo head to head
By HME News Staff
Updated Thu January 31, 2008
LONDON - Clinical trial results show Glaxo's Advair has an edge over Pfizer's Spiriva in treating patients with COPD, Reuters reported Dec. 28. A two-year study of 1,300 patients found both drugs had a similar impact on rate of exacerbations, but patients treated with Advair gained a significant improvement in health status and greater survival benefit than those on Spiriva, according to Glaxo. Results of the first head-to-head study of the two drugs were published in the American Journal of Respiratory and Critical Care Medicine.
Comments